Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease
Open accessThe DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Abstract
Background: Mucosal healing (MH) was proposed to be an ideal treatment goal for patients with inflammatory bowel disease (IBD). Instead of endoscopy to confirm MH, biomarkers are frequently used and have become an indispensable modality for the clinical examination of patients with IBD. Summary: Common biomarkers of IBD include C-reactive protein (CRP), erythrocyte sedimentation rate, antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, leucine-rich α2 glycoprotein, fecal calprotectin (FCP), and the fecal immunochemical test. Biomarkers play five major roles in the management of IBD: (1) diagnosing and distinguishing between IBD and non-IBD or ulcerative colitis and Crohn’s disease; (2) predicting treatment response, especially before administrating biologics; (3) monitoring and grasping endoscopic or histological disease activity; (4) replacing endoscopy for diagnosing MH, including endoscopic and histological remission; and (5) predicting recurrence before disease activity appears through symptoms. Many reports have demonstrated the usefulness of CRP and FCP for those five roles; however, they have limitations for diagnosing MH or predicting treatment response. In general, FCP has better ability in those positions than CRP; additionally, leucine-rich α2 glycoprotein can diagnose endoscopic disease activity better than CRP. The novel biomarker, prostaglandin E-major urinary metabolite, and anti-αvβ6 antibody are expected to be noninvasive and reliable biomarkers; however, more evidence is required for future studies. Oncostatin M and microRNA are also prospects, in addition to other familiar and novel biomarkers. Key Messages: Each biomarker has a useful feature; therefore, we should consider their features and use appropriate biomarkers for the five roles to enable noninvasive and smooth management of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“One of the primary advantages of the AI-aided fusion multimodal approach is the ability to identify and understand specific and interconnected biological alterations, enabling early and improved disease diagnosis and outcome.85”
From Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease (2024) · cites this paper as [85]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcium's Role in Mechanotransduction during Muscle Development
Benavides Damm, T., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,502
Integrins: Versatility, modulation, and signaling in cell adhesion
Hynes, R. O. (1992) · Cell · doi:10.1016/0092-8674(92)90115-s · Cited by 9,859
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 3,503
Turner, D., Ricciuto, A., Lewis, A., D’Amico, F., Dhaliwal, J., Griffiths, A. M., Bettenworth, D., Sandborn, W. J., Sands, B. E., Reinisch, W., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.031 · Cited by 2,911
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Peyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844
Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort
Frøslie, K. F., Jahnsen, J., Moum, B. A., & Vatn, M. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.051 · Cited by 1,121
Laboratory markers in IBD: useful, magic, or unnecessary toys?
Vermeire, S., Van Assche, G., & Rutgeerts, P. (2006) · Gut · doi:10.1136/gut.2005.069476 · Cited by 952
Colombel, J. F., Rutgeerts, P., Reinisch, W., Esser, D., Wang, Y., Lang, Y., Marano, C. W., Strauss, R., Oddens, B. J., Feagan, B. G., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.054 · Cited by 919
Cited by
Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments
Wangchuk, P., Yeshi, K., & Loukas, A. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.08.003 · Cited by 333
Díez-Martín, E., Hernández-Suárez, L., Muñoz‐Villafranca, C., Martin–Souto, L., Astigarraga, E., Ramirez‐Garcia, A., & Barreda‐Gómez, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137062 · Cited by 133
“Additionally, calprotectin found in fecal samples can provide a measure of specific intestinal inflammation, whereas that obtained from other fluids offers a more general measure of body inflammation [223].”
InfluentialBiomarkers in inflammatory bowel disease: a practical guide
Clough, J., Colwill, M., Poullis, A. P., Pollok, R., Patel, K., & Honap, S. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241251600 · Cited by 116
“13 For clinicians, there are also further considerations such as availability, turn-around time for testing and robustness of the analytic method used.”
MethodJiang, W. J., Yin, J., Han, M., He, W., Zhao, Y., Hu, J., Wang, M., Wang, S., Xu, J., Deng, C., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s518155 · Cited by 88
“43 Detecting the expression of N4BP3 in the blood from IBD patients and normal populations, analyzing the correlation between the expression of N4BP3 in the blood and IBD, which may provide a new method for the diagnosis of IBD.”
Iacucci, M., Santacroce, G., Zammarchi, I., Maeda, Y., Del Amor, R., Meseguer, P., Kolawole, B. B., Chaudhari, U., Di Sabatino, A., Danese, S., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00053-0 · Cited by 73
Metadata
- Authors
- Sakurai, T., & Saruta, M.
- Affiliations
- Jikei University School of Medicine (JP)
- Corresponding author
- Sakurai, Toshiyuki
- Venue
- Digestion
- Publisher
- S. Karger AG
- Published
- 2022-11-18
- Volume
- 104
- Issue
- 1
- Pages
- 30-41
- ISSN
- 0012-2823 (ISSN-L)
- 1421-9867
- PMC
- PMC9843547
- OpenAlex
- W4309466247
- Cited by
- 156
- References
- 137
- Citations by year
- 2026: 43 · 2025: 48 · 2024: 42 · 2023: 23
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Digestion (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- inflammatory bowel disease, biomarkers, mucosal healing, fecal calprotectin, C-reactive protein, LRG1, ASCA, antineutrophil cytoplasmic antibodies, fecal immunochemical test, disease activity monitoring, treatment response prediction, disease recurrence prediction, ulcerative colitis, Crohn's disease, non-invasive diagnosis, oncostatin M, microRNA
- MeSH terms
- C-Reactive Protein, Colitis, Ulcerative, Feces, Glycoproteins, Humans, Leucine, Severity of Illness Index, Inflammatory Bowel Diseases, Biomarkers, Leukocyte L1 Antigen Complex
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease. https://app.cochat.ai/papers/10.1159/000527846
- The paper
- Sakurai, T., & Saruta, M. (2023). Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease. Digestion. https://doi.org/10.1159/000527846
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.